Correspondence 0001104659-26-001751 from Adagene Inc. (ADAG)
Adagene Inc.
Date: Jan. 7, 2026 · CIK: 0001818838 · Accession: 0001104659-26-001751
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291196
Letter
Adagene Inc.
4F, Building C14, No. 218
Xinghu Street, Suzhou Industrial Park
Suzhou, Jiangsu Province,
People's Republic of China
January 7, 2026
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Lauren Hamill
Re: Adagene Inc.
Registration Statement on Form F-3
Filed October 31,
File No. 333-291196
Ladies and Gentlemen:
On behalf of Adagene Inc., (the "Company"), and pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the above-referenced Registration Statement on Form F-3 be accelerated so that it will be declared effective at 4:15
p.m. on January 9, 2026, or as soon thereafter as is practicable.
Please direct any questions regarding the foregoing to Xuelin (Steve) Wang at +852 2533-1092 (xuelin.wang@davispolk.com) of Davis Polk & Wardwell LLP, counsel to the Company.
Sincerely,
/s/ Peter Luo
Show Raw Text
CORRESP 1 filename1.htm Adagene Inc. 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People's Republic of China January 7, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Lauren Hamill Re: Adagene Inc. Registration Statement on Form F-3 Filed October 31, 2025 File No. 333-291196 Ladies and Gentlemen: On behalf of Adagene Inc., (the "Company"), and pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the above-referenced Registration Statement on Form F-3 be accelerated so that it will be declared effective at 4:15 p.m. on January 9, 2026, or as soon thereafter as is practicable. Please direct any questions regarding the foregoing to Xuelin (Steve) Wang at +852 2533-1092 (xuelin.wang@davispolk.com) of Davis Polk & Wardwell LLP, counsel to the Company. Sincerely, /s/ Peter Luo Peter Luo Chief Executive Officer Adagene Inc. cc: Xuelin (Steve) Wang, Esq.